Head-to-head evidence
HRS-7535 vs VCT220
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
HRS-7535
Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals
NCT06904105 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial (n=556). The primary endpoint, percent weight change at week 44, was met: participants lost 9.5% (120 mg) and 10.9% (180 mg) of body weight versus 2.5% with placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06820099 (registry estimate)
VCT220
Developed by Ji Xing Pharmaceuticals (CORXEL) under a licence from Vincentage Pharma
NCT06569355 · Phase 2 · completed
This Phase 2 trial randomly assigned 250 people with obesity or overweight to one of several VCT220 doses or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was percentage change in body weight at week 16. Weight fell by between 5.8% and 9.7% across the VCT220 dose groups against 1.6% on placebo, with reductions of 9.7% and 9.4% at the two 160 mg schedules (p of 0.001 or lower).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-7535's landscape · VCT220's landscape